App-Quantinova.ai

SOLUBLE GLYCOPROTEIN VI: A POTENTIAL BIOMARKER FOR DISEASE ACTIVITY AND PLATELET REACTIVITY IN GOUT

C.L. Murphy - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

Fibrinogen (IV)

DETECTION OF IGG ANTI-DOMAIN I BETA2 GLYCOPROTEIN I ANTIBODIES BY CHEMILUMINESCENCE IMMUNOASSAY IN PRIMARY ANTIPHOSPHOLIPID SYNDROME

L. Meneghel - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

N/A

EFFECTS OF NEW (DIRECT) ORAL ANTICOAGULANTS ON LUPUS ANTICOAGULANT ASSAYS

J. Antovic - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

rivaroxaban

RISK AND CHARACTERISTICS OF DRUG INDUCED VASCULITIS IN PATIENTS EXPOSED TO TUMOUR NECROSIS FACTOR ? INHIBITOR THERAPY: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR RHEUMATOID ARTHRITIS

M. Jani - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

Certolizumab pegol

INCIDENCE OF COMPLICATIONS AFTER TOTAL JOINT REPLACEMENT IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES RECEIVING BIOLOGIC TREATMENT

V.N. Khlaboschina - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

Methotrexate

EVALUATION OF VENOUS DISEASE SPESIFIC QUALITY OF LIFE IN PATIENTS WITH VASCULAR BEHCE-S DISEASE

F. Alibaz-Oner - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

BEHCE-S DISEASE COMPLICATED WITH CEREBRAL VENOUS SINUS THROMBOSIS: A REPORT OF NINE CASES

L. Akyol - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

Cyclophosphamide

ATHEROSCLEROSIS IN BEHCET DISEASE: A SYSTEMATIC REVIEW & METANALYSIS

M. Merashli - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

THROMBOSIS AND RE-THROMBOSIS MANIFESTATIONS IN PATIENTS WITH BEHCET DISEASE. DESCRIPTIVE ANALYSIS FROM REGEB COHORT

M. Rodriguez Carballeira - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

Adalimumab

CLINICAL MANIFESTATIONS AND FEATURES OF CRYOFIBRINOGENEMIA: RUSSIAN EXPERIENCE

T. Shevtsova - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

CS-359

THREE BEHCE-S DISEASE PATIENTS WITH PULMONARY ARTERY ANEURYSM

Z.S. Arici - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Cyclophosphamide

A RARE CASE OF NEONATAL ANTIPHOSPHOLIPID SYNDROME

T. Giani - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

Fibrinogen (IV)

SLE AND SS: MATERNAL AND FETAL RISKS: TREATMENT STRATEGIES

B. Bermas - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Venous thrombosis

Mycophenolate mofetil

DO PATIENTS WITH RHEUMATOID ARTHRITIS HAVE ADVERSE PROGNOSTIC FACTORS FOR VENOUS THROMBOEMBOLIC EVENTS?

M.A. Satybaldyeva - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Glucocorticoid

RISK FACTORS AFFECTING LENGTH OF HOSPITAL STAY AFTER TOTAL KNEE ARTHROPLASTY IN RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS PATIENTS

K. Kawakami - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

N/A

A PHASE 1B/2A STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF XMAB5871 IN PATIENTS WITH RHEUMATOID ARTHRITIS

M. Jaraczewska-Baumann - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

XmAb5871

SAFETY, TOLERABILITY, PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF BI 655064, AN ANTAGONISTIC ANTI-CD40 ANTIBODY IN HEALTHY VOLUNTEERS

C. Schwabe - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

BI 655064

RHEUMATOID ARTHRITIS AND REVISION SURGERY INCREASE THE RISK OF PREOPERATIVE DEEP VEIN THROMBOSIS IN PATIENTS UNDERGOING TOTAL KNEE ARTHROPLASTY

H. Wakabayashi - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

PULMONARY EMBOLISM IN OLIGOSYMPTOMATIC SYSTEMIC SCLEROSIS PATIENTS

I. Cordeiro - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

LONG-TERM OUTCOMES AND PREDICTORS OF MORTALITY IN SYSTEMIC LUPUS ERYTHEMATOSUS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: A SINGLE CENTER COHORT STUDY

J. Zhao - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

Mycophenolate mofetil

Filters

7277 Abstracts